Macro International Ltd

Astal Laboratories Limited has submitted the notice for its 33rd Annual General Meeting (AGM), scheduled for September 29, 2026. The meeting will be conducted via Video Conferencing (VC)/Other Audio Visual Means (OAVM). Key agenda items include the adoption of standalone and consolidated financial statements for FY 2025-26, along with the reports of the Board of Directors and Statutory Auditors. Additionally, a Non-Executive Director, Mr. Maggidi Venkatesh, will retire by rotation and be considered for re-appointment. The company is also complying with SEBI and MCA circulars regarding virtual meeting conduct.

Astal Laboratories Ltd has announced its 33rd Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 01:30 p.m. IST, to be conducted via Video Conference/Other Audio-Visual Means. The company is providing shareholders whose email IDs are not registered with a web-link to access the Annual Report for FY 2025-26 and the AGM notice. Key dates include Book Closure from September 23-29, 2026, and e-voting from September 26 to September 29, 2026. Shareholders are also reminded to update KYC details and dematerialize physical securities.

Astal Laboratories Ltd has submitted its Annual Report for the financial year ended March 31, 2026, in compliance with SEBI Listing Regulations. The report includes the notice for the 33rd Annual General Meeting (AGM), scheduled for Tuesday, September 29, 2026, at 01:30 P.M. via Video Conferencing/Other Audio Visual Means. The company, formerly Macro International Limited, is focusing on complex APIs in CNS and CVS segments, alongside specialty chemicals and personal-care ingredients. A web-link for accessing the AGM notice and Annual Report is being sent to members without registered email IDs.

Astal Laboratories Ltd has announced the appointment of Avnesh Jain & Co., Cost Accountants (FRN: 101048), as the company's Cost Auditors for the financial year 2026-27. The decision was approved by the Board of Directors during a meeting held on September 04, 2026. The appointment is in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. Avnesh Jain & Co. is described as a professional outfit committed to providing value-added services with high ethical standards. They have confirmed no relationship with any directors or key managerial personnel.

Astal Laboratories Ltd has announced its 33rd Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 01:30 PM via Video Conferencing/Other Audio Visual Means (OAVM). The company has set Tuesday, September 22, 2026, as the cut-off date for determining voting eligibility. The Register of Members and Share Transfer Books will be closed from September 23 to September 29, 2026. Remote e-voting will be open from September 26 to September 28, 2026.

Astal Laboratories Ltd announced the outcome of its Board of Directors meeting held on September 4, 2026. The board approved the Board Report for the financial year ended March 31, 2026. Key decisions included the appointment of M/s Avnesh Jain & Co. as Cost Auditors for FY 2026-27 and M/s. Mahendra Khandelwal & Co. as Scrutinizer for the upcoming Annual General Meeting (AGM). The 33rd AGM is scheduled for September 29, 2026, to be conducted via Video Conferencing/OAVM. The register of members and share transfer books will be closed from September 23 to September 29, 2026, for the AGM. The cut-off date for electronic voting eligibility is September 22, 2026.

Astal Laboratories Ltd has announced a Board of Directors meeting scheduled for September 4, 2026. The meeting will primarily focus on approving the Notice of the 33rd Annual General Meeting (AGM), including its date, time, and venue. Additionally, the board will consider and approve the Board Report for the financial year ended March 31, 2026, and appoint a scrutinizer for the AGM voting process. The meeting will be held at the company's corporate office in Telangana.

Astal Laboratories Ltd announced the declaration of its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results, along with the limited review report from the auditors, Sathuluri & Co. The board meeting, where these financial statements were considered and approved, commenced at 05:00 p.m. IST and concluded at 05:38 p.m. IST on August 14, 2026. The company has made this information available on its website.

Astal Laboratories Ltd announced the outcome of its Board Meeting held on August 14, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company operates in a single business segment: Manufacturing and Trading of Active Pharmaceutical Ingredients (Bulk Drugs). The financial results were reviewed by the Audit Committee and approved by the Board. The company also noted it has one material wholly-owned subsidiary.

Astal Laboratories Ltd has announced a Board of Directors meeting scheduled for August 14, 2026. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the auditors' limited review report. Additionally, the meeting will address any other business with the chair's permission. In compliance with SEBI regulations, the trading window for designated persons and their relatives will be closed from July 1, 2026, until 48 hours after the board meeting concludes.